Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection.

PURPOSE We examined the relationship between a mutant (T) for wild-type (C) allele substitution of the human kallikrein-2 gene (KLK2), circulating human kallikrein-2 (hK2) levels and prostate cancer risk. PATIENTS AND METHODS We studied 1,287 consecutive men who underwent prostate biopsies because of an abnormal prostate-specific antigen level. Serum and DNA were obtained before biopsy. Cases were patients with cancer, and controls were patients with no cancer. The mutant and wild-type alleles of the KLK2 gene were designated as the T and C alleles, respectively. RESULTS Of the 1,287 men, 616 had cancer, and 671 had no cancer. The overall distribution of the CC, CT, and TT KLK2 genotypes was 55.1%, 38.2%, and 6.8%, respectively. The median hK2 levels for men with the CC, CT, and TT genotypes were 0.24, 0.18, and 0.062 ng/mL and correlated with the genotypes, respectively (P =.0001). The adjusted odds ratios for prostate cancer for patients with the TT and CT genotypes compared with patients with the CC genotype, were 2.13 (95% confidence interval [CI], 1.3 to 3.5; P =.004) and 1.51 (95% CI, 1.2 to 2.0; P =.002), respectively. The adjusted odds ratio for prostate cancer for patients in the fourth quartile of hK2 compared with the first quartile was 4.33 (95% CI, 2.9 to 6.4; P =.0001). When combined, the adjusted odds ratio for having prostate cancer was 13.92 (95% CI, 6.6 to 29.2; P =.0001) for patients with high hK2 levels and at least one T allele. CONCLUSION The C/T polymorphism of the KLK2 gene and circulating levels of hK2 are correlated and, in combination, are highly predictive for prostate cancer.

[1]  K. Klinger,et al.  Germline mutations in the ribonuclease L gene in families showing linkage with HPC1 , 2002, Nature Genetics.

[2]  C C Schulman,et al.  Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? , 2001, The Journal of urology.

[3]  F. Mostofi,et al.  Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[4]  J. Cerhan,et al.  Role of HPC2/ELAC2 in hereditary prostate cancer. , 2001, Cancer research.

[5]  D. Gerhard,et al.  Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. , 2001, Cancer research.

[6]  G. Klee,et al.  Development of a dual monoclonal antibody immunoassay for total human kallikrein 2. , 2001, Clinical chemistry.

[7]  J. Trachtenberg,et al.  HPC2 variants and screen-detected prostate cancer. , 2001, American journal of human genetics.

[8]  J. Richie,et al.  Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. , 2000, Urology.

[9]  M. Marberger,et al.  A polymorphism in the CYP17 gene is associated with prostate cancer risk , 2000, International journal of cancer.

[10]  J. Hugosson,et al.  Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. , 2000, Urology.

[11]  J. Trachtenberg,et al.  Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Coetzee,et al.  Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. , 2000, Cancer research.

[13]  D. Tindall,et al.  Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. , 1999, Urology.

[14]  J. Holaday,et al.  Antiangiogenic activity of prostate-specific antigen. , 1999, Journal of the National Cancer Institute.

[15]  E. Diamandis,et al.  Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. , 1999, Clinical chemistry.

[16]  T. Rebbeck,et al.  GLUTATHIONE-S-TRANSFERASE (GSTM1) AND (GSTT1) GENOTYPE IN THE ETIOLOGY OF PROSTATE CANCER , 1999 .

[17]  T. Piironen,et al.  In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. , 1998, Urology.

[18]  C. Vanchieri.  Prostate cancer screening trials: fending off critics to recruit men. , 1998, Journal of the National Cancer Institute.

[19]  G. Murphy,et al.  American Cancer Society guidelines for the early detection of prostate cancer , 1997, Cancer.

[20]  H. Lilja,et al.  Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. , 1997, Biochemical and biophysical research communications.

[21]  C. Lazure,et al.  Prostatic kallikrein hK2, but not prostate‐specific antigen (hK3), activates single‐chain urokinase‐type plasminogen activator , 1997, International journal of cancer.

[22]  P. Kantoff,et al.  The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Kurkela,et al.  Human prostate-specific glandular kallikrein is expressed as an active and an inactive protein. , 1997, Clinical chemistry.

[24]  G. Coetzee,et al.  Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. , 1997, Journal of the National Cancer Institute.

[25]  B A Miller,et al.  The role of increasing detection in the rising incidence of prostate cancer. , 1995, JAMA.

[26]  S. Narod,et al.  The impact of family history on early detection of prostate cancer , 1995, Nature Medicine.

[27]  M. Stampfer,et al.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.

[28]  W. Catalona,et al.  Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. , 1994, The Journal of urology.

[29]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[30]  D. Tindall,et al.  Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5' promoter region of the gene. , 1993, Biochemistry.

[31]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[32]  P. Riegman,et al.  Characterization of the human kallikrein locus. , 1992, Genomics.

[33]  J. Oesterling,et al.  Prostate-specific antigen. Improving its ability to diagnose early prostate cancer. , 1992, JAMA.

[34]  D. Tindall,et al.  Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. , 1992, Biochemistry.

[35]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[36]  O. Lukkarinen,et al.  Expression of the gene coding for human prostate‐specific antigen and related hGK‐1 in benign and malignant tumors of the human prostate , 1990, International journal of cancer.

[37]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[38]  B. Morris,et al.  Primary structure of a human glandular kallikrein gene. , 1987, DNA.

[39]  H. Lilja.  A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. , 1985, The Journal of clinical investigation.

[40]  J. Trachtenberg,et al.  V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. , 2001, Urology.

[41]  J. Trachtenberg,et al.  Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a 'rapid riser' subset. , 1998, British journal of urology.